Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total value of $384,900.00. Following the transaction, the senior vice president now owns 168,176 shares in the company, valued at approximately $6,473,094.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Halozyme Therapeutics Stock Down 0.9 %

NASDAQ HALO traded down $0.36 during trading hours on Wednesday, hitting $38.02. 733,857 shares of the company were exchanged, compared to its average volume of 1,278,183. The company has a 50 day moving average of $39.44 and a two-hundred day moving average of $37.76. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $45.00. The firm has a market cap of $4.83 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 0.47 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HALO has been the subject of several recent analyst reports. Benchmark reissued a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday. The Goldman Sachs Group cut their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Morgan Stanley cut their price objective on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a report on Tuesday, December 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $53.29.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Halozyme Therapeutics by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 13,335,155 shares of the biopharmaceutical company’s stock worth $527,273,000 after acquiring an additional 38,342 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in shares of Halozyme Therapeutics by 3.4% in the 3rd quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock valued at $294,632,000 after purchasing an additional 253,363 shares during the period. Snyder Capital Management L P boosted its position in shares of Halozyme Therapeutics by 7.8% in the 1st quarter. Snyder Capital Management L P now owns 4,295,184 shares of the biopharmaceutical company’s stock valued at $164,033,000 after purchasing an additional 311,370 shares during the period. Macquarie Group Ltd. boosted its position in shares of Halozyme Therapeutics by 22.8% in the 1st quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock valued at $122,226,000 after purchasing an additional 595,220 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Halozyme Therapeutics by 4.6% in the 1st quarter. Geode Capital Management LLC now owns 2,631,387 shares of the biopharmaceutical company’s stock valued at $100,493,000 after purchasing an additional 116,290 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.